Serum Levels Evaluation of TMSB10 and Endocan in Breast Cancer Patients and In-Vitro Study of Chrysin Effect on These Markers in MCF-7 cell line

• Published in: Egyptian Journal of Basic and Applied Sciences 2023-12, Vol.10 (1), p.503-517
• Main Authors: Hammouda, Nada E., Samra, Yara A., Emarah, Ziad, El-Gayar, Amal M.
• Format: Article
• Language: English
• Subjects: breast cancer tumorigenesis; chrysin; endocan; MCF-7 cell line; prognosis; Thymosin beta-10
• ISSN: 2314-808X; 2314-808X
• DOI: 10.1080/2314808X.2023.2236382

Thymosin beta-10 (TMSB10) and Endocan (END) are key regulators of tumorigenesis. However, limited studies have assessed the effect of chrysin on TMSB10 and END in breast cancer (BC) cell lines. This research aimed to evaluate TMSB10 and END serum levels in BC patients. Moreover, it aimed to evaluate the effect of Chrysin on these tumor markers in MCF-7 cells. Therefore, samples were collected from 50 BC patients to evaluate TMSB10 and END serum levels as a clinical estimation trail using ELISA followed by evaluation for chrysin effect on TMSB10 and END levels as antiproliferative treatment in MCF-7 cells. Serum TMSB10 and END were significantly elevated (P = 0.002 and 0.015) in BC patients than in controls. TMSB10 and END demonstrated a sensitivity of 62% and 60%, and proved to be a prognostic indicator for metastasis at a cut-off value ≥535.6 ng/mL and 720.83 pg/mL in BC. Chrysin inhibited the growth of MCF-7 cells and suppressed the TMSB10 and END levels. Accordingly, TMSB10 and END could be prospective serum biomarkers for tumorigenesis and development of BC, while chrysin might be a promising treatment agent to halt the progression of cancer whose effectiveness needs to be further investigated.